CDKN2A and glioblastoma: These tumors molecularly showed, in addition to the FGFR3-TACC3 fusion, the conventional GBM, IDHwt features (absence of IDH1/2, ATRX and TP53 mutations, 7p gain, 10q loss, and TERT promoter mutations), except for EGFR amplification (0/29), combined with a higher incidence of CDKN2A homozygous deletions.